In addition, large randomized clinical trials of targeting the programmed cell death protein 1 (PD-1) axis have demonstrated significant antitumor activities in some later-line metastatic diseases including lung cancer (36). This evidence concerns the gene PDCD1 and metastatic neoplasm.